Core Viewpoint - The chairman of Jiaoda Anlian, Ji Min, revealed that former executives, including Yang Guoping, may be involved in illegal activities, leading to potential issues with information disclosure and internal controls within the company [2][11][19]. Group 1: "Purchase and Refund" Behavior - Jiaoda Anlian's "purchase and refund" behavior began in November 2022 when tax authorities requested a review of related matters, revealing inconsistencies between the number of insured and beneficiaries [3][9]. - In October 2016, Jiaoda Anlian invested 3.8 million yuan to purchase group insurance, with the insured being former executives, including Yang Guoping and Zhu Minjun [3][9]. - In April 2017, Yang Guoping signed for the refund as the legal representative of the insured unit, resulting in a total refund of 3.7924 million yuan to the personal accounts of five individuals, excluding beneficiary Ge Jianqiu [6][9]. Group 2: Internal Control and Disclosure Issues - Ji Min emphasized that Jiaoda Anlian has not disclosed the "purchase and refund" matters in any announcements, raising concerns about internal controls and information disclosure [11][12]. - The Shanghai Securities Regulatory Commission issued a warning to Jiaoda Anlian for violations, including inaccurate disclosures of executive compensation in annual reports for 2016 and 2018 [13][19]. - There is no record of the original documents related to the board and shareholder meetings approving the relevant proposals, raising questions about their legitimacy [16][18]. Group 3: Potential Conflicts of Interest - Ji Min indicated that the actions of former executives, particularly Ge Jianqiu, could reveal multiple capital operations that may involve conflicts of interest and insider trading [26][31]. - Jiaoda Anlian acquired a 22.97% stake in Tai Ling Pharmaceutical, with Ge Jianqiu serving as a non-executive director there, which raises suspicions of benefit transfer and insider trading [31][36]. - From October 2016 to January 2020, Jiaoda Anlian's investment in Tai Ling Pharmaceutical resulted in significant losses, with the stock price dropping over 80% during that period [36][38].